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ABSTRACT IgG molecules can be highly tolerogenic car-
riers for associated antigens. Previously, we reported that
recipients of bone marrow or lipopolysaccharide-stimulated
B-cell blasts, both of which were retrovirally gene-transferred
with an immunodominant peptide in-frame with the variable
region of a murine IgG heavy chain, were rendered profoundly
unresponsive to that epitope. To further investigate whether
tolerance to larger molecules can be achieved via this ap-
proach and whether the IgG scaffold is important for induc-
tion and maintenance of immunological tolerance, we engi-
neered two retroviral constructs encoding the cI l repressor
(MBAE-1–102 and MBAE-1–102-IgG) for gene transfer. Our
results show that recipients of bone marrow or peripheral B
cells, transduced with the MBAE-1–102-IgG recombinant, are
hyporesponsive to p1–102. In addition, the self-IgG scaffold
enhanced the induction and maintenance of such an immune
hyporesponsiveness. Thus, our studies demonstrate that in
vivo-expressed IgG heavy chain fusion protein can be pro-
cessed and presented on the appropriate MHC class II,
resulting in hyporesponsiveness to that antigen and offering
an additional therapeutic approach to autoimmune diseases.
Individuals normally develop tolerance to self-constituents
during the development of the immune system. Tolerance
induction, however, is a lifelong process and also must occur
extrathymically (1). Moreover, the maintenance of this unre-
sponsive state requires the persistence of antigen and contin-
ued induction in adults (2). The failure to discriminate between
immunological self and nonself components leads to the
clinical manifestations of autoimmunity. A number of exper-
imental procedures have been proposed to induce tolerance to
autoantigens and therefore to prevent andyor reverse auto-
immune diseases (3–5), although tolerance induction and
maintenance in mature animals has proven difficult. Hence,
novel methods need to be developed to promote tolerance
induction in immunocompetent adults and to express the
tolerogen in multipotential hematopoietic compartments for
persistence of tolerogen and long-term maintenance of toler-
ance.
Peptide fragments of multideterminant antigens can be
divided into three main groups: dominant, subdominant, and
cryptic epitopes (6–8). An immunodominant epitope is a
peptide fragment specifically processed by antigen-presenting
cells from a larger, multideterminant antigen and varies indi-
vidually as a function of its MHC. Such an epitope is capable
of binding to the MHC molecule, and this peptideyMHC
complex then is recognized by the T-cell repertoire (6, 7).
Subdominant epitopes are the determinants that can stimulate
native protein primed cells to proliferate, but less than dom-
inant epitopes or the whole protein (7, 8). In contrast, cryptic
determinants are rarely revealed during antigen processing
and therefore fail to activate T cells when the native antigen is
used as immunogen (7, 8). However, these hidden determi-
nants might play a role in pathogenic autoimmune responses.
One of the pathophysiological mechanisms that may explain
the unveiling of these minor epitopes is determinant spreading
(9, 10).
Immunoglobulins have been used as carriers to induce T-
and B-cell tolerance to their own and associated epitopes, with
isologous IgG carriers being the most efficacious (11, 12).
Recently, Zambidis et al. (13) demonstrated the specific
tolerogenic properties in adult BALByc mice of a chimeric
molecule consisting of residues 12–26 of the cI l repressor
protein (p1–102) fused to the N terminus of a murine IgG H
chain. In addition, animals receiving retrovirally encoded
12–26-IgG were shown to be profoundly unresponsive to the
12–26 peptide at both the humoral and cellular levels (14).
In cases where immunodominant epitopes have not yet been
mapped, it would be desirable to fuse the entire protein to the
IgG scaffold for tolerance induction. However, it is unclear
whether a chimeric molecule consisting of full-length protein
would be efficiently processed and presented and in turn
tolerize as effectively as selected epitopes. Furthermore, it is
unclear whether the IgG scaffold is essential for induction and
maintenance of tolerance.
To address these questions, we established two MBAE
retroviral constructs encoding either p1–102 or p1–102-IgG
heavy chain. The constructs were used to transduce B cells or
bone marrow (BM) cells, which were adoptively transferred to
syngeneic mice to test for tolerance. When challenged with
p1–102, mice receiving either LPS B-cell blasts or BM trans-
duced with the 1–102-IgG-encoding gene failed to respond as
effectively as the mock controls to the major epitopes of
p1–102 recognized by mice of these haplotypes. Moreover,
compared with 1–102 alone, the 1–102-IgG fusion protein was
more effective in the induction of hyporesponsiveness. The
former induced only a transient form of hyporesponsiveness,
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suggesting that the IgG scaffold is important in the mainte-
nance of tolerance. These results show that retrovirally medi-
ated transfer of a gene encoding full-length protein fused to
IgG is an effective approach for the purpose of inducing
hyporesponsiveness to multiple epitopes.
MATERIALS AND METHODS
Mice. CB6 F1 mice were purchased from The Jackson
Laboratory at 6–8 weeks of age and housed in pathogen-free
micro-isolater cages in our animal facility.
Retroviral Constructs Encoding cI l p1–102 or p1–102-IgG
and Virus Producer Cell Lines. A 320-bp DNA fragment
encoding p1–102 was amplified by PCR (30 cycles: 94°C, 15
sec; 55°C, 15 sec; 72°C, 1.5 min) from pRB104 (a kind gift from
Richard M. Breyer, Vanderbilt Medical Center, Nashville,
TN). The 59 primer, GCG GTC GAC ATG AGC ACA AAA
AAG AAA CC, contained a SalI restriction site and N-
terminal sequences of 1–102; the 39 primer, CGC AAG CTT
CTA CTA CTC ATA CTC ACT TCT AAG TGA, contained
a HindIII restriction site and translational stop codon se-
quences. DNA polymerase fidelity was confirmed by subclon-
ing the PCR product into pCRII vector (Invitrogen) and
sequencing both DNA strands with universal cycle primer and
reverse cycle primers (Amersham Life Science). The amplified
p1–102 DNA fragment was cloned into SalIyHindIII restric-
tion sites of the Moloney leukemia retroviral vector MBAE
(14, 15).
For the p1–102-IgG construct, a 320-bp DNA fragment
encoding p1–102 was PCR-amplified by using 59 and 39 primers
containing a NotI restriction site and a SalI site, respectively.
The p1–102 DNA subsequently was inserted into the VH
sequence of a murine IgG1 heavy chain between the 59 first
framework region (FR1) and FR1 repeat. The resulting p1–
102-IgG fragment, which included the leader sequence, VH
region inserted with p1–102, DJC region, and stop codon
sequences, then was subcloned into MBAE downstream of a
human b-actin promoteryenhancer (14, 15). As the original
murine IgG1 heavy chain binds with high affinity to the
nitroiodophenyl (NIP) hapten when assembling with l light
chain, the recombinant 1–102-IgG fusion protein can be
detected with a NIP-gelatin binding ELISA, although this is an
underestimate of secreted IgG fusion protein (13, 14, 16).
Virus-producer cell lines (F5.19 and F12.7) were prepared
by lipofection of c-2 packaging cell lines with p1–102-MBAE
and p1–102-IgG-MBAE retroviral constructs, respectively,
and were found to be helper virus free and to contain '105–106
(usually $5 3 105) neomycin-resistant NIH 3T3 colony-
forming unityml, by using methods as described (14, 15).
Either c-2 parental cells or 52y139 virus-producer cell line was
used as mock control. Virus-producer cell line 52y139 is a c-2
packaging cell line lipofected with MBAE retroviral construct
encoding an irrelevant epitope in-frame with the murine IgG1
scaffold (17).
Purification of 63His-1–102 Protein and Synthesis of An-
tigenic Peptides. A recombinant 63His-tagged 1–102 protein
was engineered by subcloning the p1–102 DNA fragment into
the pQE-31 vector (QIAgen Expressionist Kit, Qiagen, Va-
lencia, CA) and transforming Escherichia coli M15 (pREP4)
(QIAgen Expressionist Kit). The p1–102 protein was prepared
and purified by using a Ni-nitrilotriacetic acid column accord-
ing to the manufacturer’s instructions. Eluted p1–102 fractions
were dialyzed against PBS (pH 7. 2), filter-sterilized, and
antigenically verified by ELISA and Western blot analysis
(data not shown). Western blot analysis was performed by
using the mAb B3.11, specific for the 12–26 epitope of p1–102
(13, 14).
The major antigenic peptides of p1–102 in H-2d, H-2b, and
H-2k mice, residues 12–26 (LEDARRLKAIYEKKK), resi-
dues 73–88 (VEEFSPSIAREIYEMY), and residues 55–69
(NALNAYNAALLAKIL), respectively (6, 18) were synthe-
sized in the Molecular Biology Core of the Holland Laboratory
by using a solid-phase method and were purified to $95%
homogeneity by HPLC.
Retroviral-Mediated Gene Transfer to BM and LPS-
Stimulated B-Cell Blasts. Retroviral-mediated gene transfer
into BM and bacterial LPS (E. coli 055:B5, Sigma)-stimulated
splenic B cells has been described (14, 15, 19). Briefly, cells
were cultured (3 3 106yml, 5 ml cultures) for 48 hr with
irradiated (2,000 rad) F5.19yF12.7 or mock control packaging
cell lines in the presence of 6 mgyml of polybrene and either
50 mgyml of LPS for B-cell blasts or 200 unitsyml of IL-3, IL-6,
and IL-7 (Genzyme) for BM. For adoptive transfer of BM,
adult CB6 F1 mice exposed to 400-rad irradiation were injected
i.v. with 1–2 3 106 gene-transferred or mock-transduced BM
cells. For adoptive transfer of LPS B-cell blasts, nonirradiated
CB6 F1 mice were injected with at least 1 3 107 transduced LPS
blasts.
Immunologic Protocols. Ten days after receiving transduced
LPS B-cell blasts or 6–8 weeks in the case of adoptive transfer
of BM, the mice were s.c. immunized in one footpad and at the
base of tail with 20 mg of recombinant 63His-p1–102 protein
emulsified 1:1 in complete Freund’s adjuvant (CFA) or with 20
mg of hen egg lysozyme (HEL) in CFA as a specificity control.
Two weeks later, mice were bled for the measurement of serum
primary antibody responses. The mice then were either sacri-
ficed and cellular immune responses in lymph nodes and spleen
determined or boosted i.p. with 20 mg of 63His-p1–102 protein
and 20 mg of HEL in PBS. The secondary antibody responses
were measured from sera collected 1 week after the boosting.
Serum p1–102-specific or HEL-specific IgG responses were
determined by ELISA by coating plates with 50 mgyml of
synthetic peptide or 1 mgyml of HEL or p1–102. Antibody IgG
titers were calculated as the dilution of test serum needed to
reduce the signal to preimmune level. Splenic memory T cell
responses were measured in vitro 1.5–5 months after secondary
challenges by using [3H]thymidine incorporation, as described
(14). IL-2 production (24-hr supernatants) was determined by
either measuring CTLL-2 proliferation or ELISA by using
Cytoscreen immunoassay kit (BioSource International, Cam-
arillo, CA). Murine IL-4 and IFN-g (48-hr supernatants) were
determined by sandwich ELISA methods using the antibodies
from PharMingen and recombinant cytokines as standards.
Relative differences in cytokine levels at a given dose of
antigen were used to estimate the degree of hyporesponsive-
ness.
Semiquantitative Genomic DNA PCR Analysis and Reverse
Transcription–PCR (RT-PCR). Genomic DNA and total
RNA were isolated from BM and spleen tissues from recipient
mice and the p1–102 sequence was amplified from total RNA
after first-strand synthesis (RT-PCR) or from genomic DNA.
The amplified products were verified by Southern blot using
p1–102 DNA as probe, as described (14, 20). The endogenous
murine b-actin fragment was coamplified with 59 primer, AAG
AGA GGT ATC CTG ACC CTG, and 39 primer, ATC CAC
ATC TGC TGG AAG GTG. Genomic DNA and RNA from
A20.2J cells transfected with 1–102y1–102-IgG genes were
used for semiquantitation (20).
RESULTS
Recipient Mice of BM and LPS B-Cell Blasts Transduced
with MBAE-1–102-IgG Are Hyporesponsive to p1–102 and Its
Dominant Epitopes in H-2bxd. Previously (14), we demon-
strated that LPS B-cell blasts and BM cells transduced with the
immunodominant epitope of p1–102 in-frame with an IgG
heavy chain resulted in specific tolerance to that epitope.
Immune responses to p1–102 in various MHC backgrounds
have been well documented (6, 18). That is, BALByc (H-2d)
and C57BLy6 (H-2b) mice predominantly recognize epitopes
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contained in residues 12–26 and 73–88, respectively (6, 18),
whereas F1 offspring between these two strains, CB6 F1 mice
(H-2bxd), recognize both 12–26 and 73–88 (Y.K. and D.W.S.,
unpublished work). Consequently, we wanted to test whether
the full-length p1–102 molecule fused to an IgG heavy chain
could be processed in a tolerogenic manner and if the re-
sponses to its major epitopes also would be reduced.
To test the tolerogenicity of 1–102-IgG-transduced LPS
B-cell blasts, purified splenic B cells from CB6 F1 mice were
stimulated with LPS, cocultured with F12.7 packaging cells,
and subsequently injected i.v. into immunocompetent synge-
neic CB6 F1 mice. The efficacy of gene transduction was
confirmed by detection of NIP hapten-specific p1–102-IgG
recombinant protein in the sera of recipient mice, as well as by
measurement of p1–102 mRNA expression in the spleen
samples (data not shown; see refs. 14 and 20 and later in Fig.
7). As shown in Fig. 1, injection of 1–102-IgG-gene-transferred
LPS blasts resulted in specific cellular hyporesponsiveness to
the dominant epitopes of p1–102 in a H-2bxd background
(p12–26 and p73–88). Moreover, all of the mice produced
comparable anti-HEL IgG titers (data not shown), whereas
there was 3- to 5-fold reduction in the antibody response to
p1–102 in recipients of 1–102-IgG-transfected blasts (P , 0.05,
Fig. 2, Upper). Specific antibody responses to H-2d and H-2b
immunodominant epitopes (12–26 and 73–88, respectively)
were also significantly lower in the 1–102-IgG recipient mice
than in mock controls (P , 0.05, Fig. 2, Lower).
In addition, the cytokine production in response to recall
antigen (p1–102) was determined from in vitro cell culture
supernatants. As shown in Fig. 3, a more than 3-fold reduction
of IL-2 (based on relative amounts of cytokine produced at a
given dose of antigen) and a less dramatic but significant
inhibition of IFN-g and IL-4 were demonstrated in recipient
mice of MBAE-1–102-IgG-transduced LPS B-cell blasts, sug-
gesting that this treatment also induced hyporesponsiveness in
both CD4 Th1 and Th2 cell compartments.
To develop a more effective tolerogenic protocol, we gen-
erated BM chimeras in sublethally irradiated (400 R) CB6 F1
mice by infusing syngeneic donor BM cells that had been
retrovirally transduced with 1–102-IgG heavy chain. The BM
chimeras then were immunized with p1–102 as well as HEL in
complete Freund’s adjuvant. Because genetically modified BM
possesses the potential to tolerize the reconstituting immune
FIG. 1. T-cell responses to the dominant epitopes of p1–102 in CB6
F1 recipients of 1–102-IgG-transduced LPS B-cell blasts. CB6 F1 mice
were injected with mock-transduced or F12.7 gene-transduced LPS
B-cell blasts. Mice then were immunized with p1–102 and HEL. Two
weeks later, lymph nodes were restimulated with dilutions of synthetic
peptides, representing H-2d (p12–26, Left) or H-2b (p73–88, Right)
immunodominant epitopes and pulsed with [3H]thymidine. The in-
corporated [3H]thymidine was detected by using a direct beta counter.
One set of representative experiments is shown, with 3–5 mice per
group. All mice respond equally to HEL. Stimulation index refers to
(cpm/backgroup cpm). Background cpm vary from 150 to 300 in this
set of experiments. Data are presented as mean 6 SE.
FIG. 2. Antibody responses to p1–102 and epitopes in CB6 F1
recipients of 1–102-IgG-transduced B-cell blasts. CB6 F1 mice were
pretreated as described in Fig. 1. Mice were primed and boosted with
p1–102 and HEL. Antibody IgG immune response was measured by
ELISA. One set of representative experiments is shown, with 3–4 mice
per group. All mice respond equally to HEL.
FIG. 3. Cytokine responses to p1–102 in CB6 F1 recipients of
1–102-IgG-transduced B-cell blasts. CB6 F1 mice were pretreated and
immunized as described in Fig. 1. One set of representative experi-
ments is shown, with 3–5 mice per group. Data are presented as
mean 6 SE.
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repertoire, we expected that recipient mice would have a more
profound form of tolerance than seen in animals receiving the
gene-transduced LPS blasts (Fig. 4). The pattern of hypore-
sponsiveness between these two protocols is similar. Impor-
tantly, more than a one log reduction of anti-p1–102 IgG titers
was found in recipient mice of MBAE-1–102-IgG-transduced
BM cells (P , 0.05) and unresponsiveness to its multiple
epitopes also was observed, including a reduction in the
antibody response to the 55–69 epitope, which is regarded as
a minor determinant in H-2bxd MHC haplotype (Fig. 4). This
result agrees with the notion that tolerized mice are unrespon-
sive both to the major and minor epitopes. T cell in vitro
proliferation to the dominant epitopes of p1–102 was signifi-
cantly reduced (data not shown), and the cytokine responses
to p1–102 also were significantly suppressed in the recipient
mice of 1–102-IgG transduced BM (see Fig. 6).
The IgG Scaffold Favors Long-Lasting Hyporesponsiveness
at Both Cellular and Humoral Levels. To address the question
of whether the self IgG scaffold is important in the induction
and maintenance of such a hyporesponsiveness, we con-
structed a MBAE retroviral vector encoding the 1–102 DNA
sequence without the self IgG scaffold. The MBAE-1–102
retroviral vector was constructed by insertion of a 1–102 DNA
fragment downstream of the b-actin promotoryenhancer in
the absence of a leaderysecretion signal sequence, whereas the
MBAE-1–102-IgG used above was similarly constructed but
with an IgG heavy chain leader sequence. Nonetheless, only
1y3–1y2 of the latter recipients had a detectable level of
NIP-specific IgG circulating in the serum (data not shown),
which may reflect either the insensitivity of this assay to detect
minimal amounts of secreted 1–102-IgG or an underestimate
because the 1–102-IgG1 heavy chain binds to NIP only when
it assembles with a l light chain.
Groups of CB6 F1 mice were injected as above with either
LPS B-cell blasts or syngeneic BM cells that had been retro-
virally transduced with 1–102 or 1–102-IgG heavy chain.
Subsequently, recipients were immunized and boosted with
p1–102 and HEL, and antibody responses were measured
before and after the boosting. Interestingly, although injection
of 1–102 gene-transferred LPS and BM could induce a state of
hyporesponsiveness to p1–102 primary immunization, this
state was not long-lasting, based on the humoral responses to
secondary challenge (Fig. 5 A and B). In contrast, 1–102-IgG
gene-transmitted CB6 F1 recipients maintained a state of
stable and long-lasting hyporesponsiveness at the humoral
levels. Furthermore, as shown in Fig. 6, the IgG scaffold favors
a long-lasting immune hyporesponsiveness at the T-cell level as
well. The splenic memory T-cell responses were measured
1.5–5 months after secondary challenge. Compared with p1–
102 recipients, the p1–102-IgG recipients demonstrated a
much more significant inhibition in T cell in vitro proliferation
and cytokine production in response to recall antigens (Fig. 6).
These results strongly suggest that the self IgG plays a crucial
role in induction and maintenance of immunological tolerance.
The difference between these groups cannot be attributed to
gene expression, because as shown in Fig. 7 there were
comparable levels of RNA expression in both groups. More-
over, long-term proviral DNA integration and p1–102 expres-
sion can be seen in BM and spleen tissues at 8 months after BM
gene transfer (Y.K. and D.W.S., unpublished data).
DISCUSSION
The goal of the present study was to examine whether a gene
therapy approach could be used to induce tolerance or hypo-
responsiveness to multiple epitopes in a full-length protein. By
using p1–102 as a model foreign antigen, we demonstrate
herein that both LPS B-cell blasts and BM cells transduced
with a retroviral recombinant encoding p1–102 in-frame with
murine g heavy chain are tolerogenic, resulting in specific
hyporesponsiveness to p1–102 and its dominant epitopes at
both cellular and humoral levels.
Residues 55–69 of p1–102 are recognized by T cells in I-Ak
mice but may be considered a minor or cryptic epitope in
I-Abxd animals (6, 18). Cryptic epitopes usually are not pro-
cessed and presented by antigen-presenting cells from the
native protein (7, 8). If these cryptic determinants become
visible, they can trigger pathogenic autoimmune responses (9,
10, 21). Therefore, it is desirable for a potential therapeutic
approach to be able to turn off the responses not only against
the major epitopes but also against the minor epitopes. Our
results suggest this may be possible. Antibody titers to p12–26,
p73–88, and p55–69 were reduced in CB6 F1 recipient mice of
adoptive BM transfer.
It is noteworthy that the responses against p1–102 in the
recipient mice of BM and LPS B blast transduced with
MBAE-1–102-IgG are only partially reduced. This specific
hyporesponsiveness, however, might be sufficient to eliminate
the pathophysiological processes in an autoimmune response.
By using a similar approach, with a major pathogenic epitope
of interphotoreceptor retinoid binding protein, Agarwal et al.
(17) demonstrated that this form of gene therapy induced
epitope-specific protection in experimental autoimmune uve-
itis. Interestingly, many parameters of immune responsiveness,
such as T-cell proliferation and in vitro IL-2 and IFN-g
production, were only partially suppressed (17).
Note that the 63His-tagged p1–102 used in our current
study was prepared from transformed E. coli M15 bacteria.
Because it is not uncommon for such a preparation to be
contaminated with trace, highly immunogenic bacterial prod-
ucts, the effect of gene therapy for a particular protein
(p1–102) may be underestimated with this immunogen. In
contrast, this is not the case with purified peptides as targets
(14).
A potential clinical therapy depends on its capability of
reversing an ongoing autoimmune response. Although not yet
tested with our current p1–102-IgG construct, results with
12–26-IgG and interphotoreceptor retinoid binding protein-
IgG clearly demonstrate that such an approach could reverse
FIG. 4. Humoral hyporesponsiveness to p1–102 in CB6 F1 mice
receiving 1–102-IgG-transduced BM. CB6 F1 mice were irradiated
with 400 rad and injected with mock-transduced or F12.7 gene-
transduced BM cells. Mice were primed and boosted with p1–102 and
HEL. Left Y ordinate represents the IgG titer against p1–102, and the
right Y ordinate represents the titers against epitopes. Antibody IgG
titers against p1–102 and p73–88 in recipient mice of F12.7 transduced
BM (filled columns) are significantly lower than those in mock controls
(empty columns) (P , 0.05). Note that antibody against the minor
epitope (p55–69) also is reduced in the recipient mice of F12.7-
transduced BM.
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established immunity. Agarwal et al. (17) showed that multiple
infusions of retrovirus-transduced B cells could protect primed
recipients from experimental autoimmune uveitis. Though
resting B cells from 12–26-IgG-expressing transgenic mice had
no effect on an ongoing immune response, LPS-stimulated
B-cell blasts from such transgenic mice induced tolerance in
BALByc mice already primed for up to 3 months (16, 22).
These data suggest a potential usefulness of our gene therapy
in a clinical setting, e.g., in diabetes.
Self-tolerance is critical in the maintenance of homeostasis
of the immune system and can occur during T- and B-cell
maturation in the thymus and BM, or in the periphery, leading
to central tolerance and peripheral tolerance, respectively (1,
23, 24). In our studies, recipient mice reconstituted by BM may
recognize p1–102 as a self-antigen and induce both central and
peripheral tolerance, whereas LPS B-blast recipients may
induce tolerance only via peripheral mechanisms. Neverthe-
less, the use of LPS B-cell blasts transduced with a gene-
encoding antigen has advantages over BM gene transfer by the
relative simplicity of the approach and the lack of a require-
ment for myeloablation. We expect that repeated injections of
gene-transduced LPS B-cell blasts at appropriate intervals
would produce a much more profound state of unresponsive-
ness than a single injection, which is true with the experimental
autoimmune uveitis animal model. Although no protection
was observed with a single bolus of retrovirus-transduced LPS
B blasts in the primed animals, three infusions at 2-day
intervals significantly reversed the established experimental
autoimmune uveitis (17).
The mechanism underlying tolerance induced by gene-
transferred LPS B-cell blasts is not yet fully understood. By
using transgenic mice expressing 12–26-IgG constitutively in B
FIG. 5. Efficacy in tolerance induction and maintenance between 1–102-IgG and 1–102 gene transfer. (A) LPS blast recipients. (B) BM
recipients. (Upper) Primary immune response. (Lower) Secondary immune response.
FIG. 6. Difference in memory T-cell responses between 1–102-IgG
and 1–102 gene transfer. CB6 F1 mice were pretreated, immunized,
and boosted as described in Fig. 4. T-cell proliferation and cytokine
production of splenic T cells was measured 1.5 months after immu-
nization. One set of representative experiments is shown, with five
mice per group. Data are presented as mean 6 SE.
FIG. 7. Comparable levels of p1–102 mRNA expression between
1–102-IgG and 1–102. Spleen samples from the same recipients as in
Fig. 6 were harvested (approximately 4 months after gene transfer),
and the p1–102-specific mRNAs were measured by reverse transcrip-
tion–PCR followed by Southern blotting using p1–102 as a probe.
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cells, we did not observe any general defect in antigen-
presenting cell capacity of these transgenic B cells (22). It is
well known that productive T-cell activation requires at least
two signals (25), as does B-cell activation. Although it is known
(26, 27) that small, resting B cells are effective at inducing
tolerance because of the lack of costimulatory molecules, this
may be an oversimplification because LPS B-cell blasts are
B7.11 and B7.2high.
Under appropriate circumstances, activated B-cell blasts
may present specific epitopes in a tolerogenic manner to T cells
(14, 16, 28). Gene-transduced LPS-activated B cells may serve
as antigen-presenting cells, providing T cells with costimula-
tory signals and suboptimal TCR engagement and resulting in
back-signaling to T cells to up-regulate CTLA-4 molecule, the
negative regulatory costimulatory molecule on T cells (29).
Hence the B7-CTLA-4-mediated negative signaling pathways
on the transduced and activated LPS B-cell blasts may play a
dominant role and, therefore, prevent T-cell activation and
proliferation. Consistent with this hypothesis, our most recent
data demonstrated that blocking B7-CTLA-4 interaction in
vivo by i.v. injection of anti-CTLA-4 antibodies reversed
hyporesponsiveness induction (30).
During the last decade, retroviruses have been used for the
expression of different genes as a prelude for human gene
therapy (31). Expression of the retrovirally transmitted genes
could be detected for more than 4–8 months (Fig. 7 and ref.
15). The majority of virally encoded proteins in the cytosolic
compartment are processed and presented by the infected cells
as MHC class I-peptide complexes for interaction with CD8 T
cells (32). However, in some cases, endogeously derived pep-
tides also can be routed to endocytic class II MHC compart-
ments (14, 33, 34). Our previous (14) and current studies
demonstrate that retrovirally transduced foreign protein in-
frame with g heavy chain can induce MHC class II-restricted
tolerance, manifested by hyporesponsiveness to that protein at
both the CD4 T cell level and antibody production. This finding
may be the result of the efficient nature of the Ig secretory
pathway in targeting the endosomal MHC class II compart-
ment. Because a fusion protein built on an IgG heavy chain
scaffold would not be secreted unless assembled with light
chains, B cells would have a selective advantage in antigen
presentation of locally secreted molecules.
Finally, expression of p1–102-IgG mediates a more effective
and longer-lasting hyporesponsiveness than p1–102 alone
(Figs. 5 and 6). We cannot rule out the possibility that the
difference seen may be the result of more efficient secretion of
p1–102-IgG into the bloodstream than that of p1–102 alone.
Thus, the latter still may induce efficient tolerance in the CD81
T cell compartment whereas the former causes more effective
CD4 T-cell tolerance. However, it also is noteworthy that the
efficacy of tolerance induction need not correlate with levels
of gene expression (14, 20).
In summary, the data presented in this report have impli-
cations for designing gene therapy strategies for modulating
antigen-specific immunity. Tolerance or even hyporesponsive-
ness to certain foreign proteins as well as autoimmune antigens
may be useful in numerous clinical situations. More impor-
tantly, the ability to express such a construct in BM allows one
to create tolerogens and to have the host produce such fusion
proteins for the induction and maintenance of unresponsive-
ness to disease-inducing epitopes.
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